Base editing rescue of spinal muscular atrophy in cells and in mice
Arbab et al. (2023). Science·Citations: 139Research
Spinal muscular atrophy therapies raise SMN protein only about 2-fold or require repeated dosing, and permanent correction of the SMN2 C6T splicing defect had not been tested. This study compared 79 nuclease and base editing strategies and found that an AAV9-delivered adenine base editor converts SMN2 T6>C in 87% of transduced cortical cells and, with nusinersen, extends Δ7SMA mouse lifespan to an average of 111 days.
Parts & designs used
Author abstract
Spinal muscular atrophy (SMA), the leading genetic cause of infant mortality, arises from survival motor neuron (SMN) protein insufficiency resulting from SMN1 loss. Approved therapies circumvent endogenous SMN regulation and require repeated dosing or may wane. We describe genome editing of SMN2 , an insufficient copy of SMN1 harboring a C6>T mutation, to permanently restore SMN protein levels and rescue SMA phenotypes. We used nucleases or base editors to modify five SMN2 regulatory regions. Base editing converted SMN2 T6>C, restoring SMN protein levels to wild type. Adeno-associated virus serotype 9–mediated base editor delivery in Δ7SMA mice yielded 87% average T6>C conversion, improved motor function, and extended average life span, which was enhanced by one-time base editor and nusinersen coadministration (111 versus 17 days untreated). These findings demonstrate the potential of a one-time base editing treatment for SMA.
Identifiers & revision
DOI 10.1126/science.adg6518OpenAlex W4361255733PubMed 36996170
